This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

48/100

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Mild cognitive impairment

Topic: Amyloid, tau and blood-test diagnosis

< 0.001). Receiver operating characteristic (ROC) analysis identified right hippocampal MD and t-tau as optimal classifiers for AD. The framework reveals distinct biomarker trajectories: DTI-ALPS distinguishes symptomatic AD from preclinical stages, while right hippocampal MD progression reflects tau-mediated neurodegeneration. Early FA reductions in MCI combined with CSF profiles suggest a hierarchical staging model: amyloid-associated perivascular dysfunction is associated with asymmetric tau-driven hippocampal degeneration. This multimodal approach provides clinically actionable biomarkers for AD progression monitoring.

Key findings

Receiver operating characteristic (ROC) analysis identified right hippocampal MD and t-tau as optimal classifiers for AD.
The framework reveals distinct biomarker trajectories: DTI-ALPS distinguishes symptomatic AD from preclinical stages, while right hippocampal MD progression reflects tau-mediated neurodegeneration.
Early FA reductions in MCI combined with CSF profiles suggest a hierarchical staging model: amyloid-associated perivascular dysfunction is associated with asymmetric tau-driven hippocampal degeneration.
This multimodal approach provides clinically actionable biomarkers for AD progression monitoring.

Why it matters

This cross-sectional study identified imaging and fluid biomarkers that distinguish different stages of Alzheimer's disease and suggest a staging model of progression. It provides potential markers for monitoring progression but does not test any treatment, cure, or prevention.

Study details

Study designcross-sectional
Evidence strengthLow

How this study scored 48/100

Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 46 of the 96 points we could judge it on, which is 48 out of 100.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Frontiers in Aging Neuroscience)
Journal's citation record	2 / 4	Frontiers in Aging Neuroscience: journal h-index 174 (OpenAlex, 2026-10-29)
Study design	4 / 12	A snapshot of people at one point in time
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	3 / 7	Cited 34 times (OpenAlex, 2026-10-10)
Citations per year	3 / 5	11.3 citations a year over 3 year(s) since 2025
Impact for its field and year	5 / 6	Cited 21.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	2 / 4	Cited 34 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	— / 4	Senior author's record not available — left out of this score
Institution's track record	0 / 3	Nanjing Medical University: institution h-index 508 (OpenAlex)
Multi-centre collaboration	1 / 3	OpenAlex lists 3 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 40791246)
Free to read	2 / 2	Free to read
Points	46 / 96	Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 46 of the 96 points we could judge it on is 48 out of 100.
Total	48 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Yu, P., Shen, L., & Tang, L. (2025). Multimodal DTI-ALPS and hippocampal microstructural signatures unveil stage-specific pathways in Alzheimer’s disease progression. Frontiers in Aging Neuroscience. https://doi.org/10.3389/fnagi.2025.1609793

Vancouver

Yu P, Shen L, Tang L. Multimodal DTI-ALPS and hippocampal microstructural signatures unveil stage-specific pathways in Alzheimer’s disease progression. Frontiers in Aging Neuroscience. 2025. doi:10.3389/fnagi.2025.1609793. PMID: 40791246.

BibTeX

@article{yu2025-40791246,
  author  = {Yu, Peng and Shen, Lu and Tang, Lijun},
  title   = {{Multimodal DTI-ALPS and hippocampal microstructural signatures unveil stage-specific pathways in Alzheimer’s disease progression}},
  journal = {Frontiers in Aging Neuroscience},
  year    = {2025},
  doi     = {10.3389/fnagi.2025.1609793},
  pmid    = {40791246},
  url     = {https://doi.org/10.3389/fnagi.2025.1609793}
}

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Mild cognitive impairment

Also tagged “classification”

835 studies in the library carry the topic tag “classification”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 835 tagged studies.

Similar studies

More on Mild cognitive impairment

See all studies in Mild cognitive impairment →